How to judge the effect of surgical treatment for ovarian cancer

The purpose of surgical treatment for ovarian cancer patients is to control the recurrence of cancer, or to delay or postpone the recurrence. So how do we judge the therapeutic effect of ovarian cancer surgery?

First, let's understand a few concepts: clinical complete remission, tumor progression, and tumor recurrence. If after a period of treatment, tumor markers, clinical examinations, imaging examinations, and PET are all negative, it is called clinical complete remission; if during treatment, the tumor reappears, or the tumor marker does not decrease or increases after decreasing, it is called tumor progression; after clinical complete remission, if the tumor marker increases again or the tumor is found by physical examination or imaging examination, it is tumor recurrence.

For patients with ovarian cancer who have not undergone complete surgical resection, the following indicators are used to judge the effectiveness of treatment:

Complete remission (CR): All lesions disappear completely and last for more than 4 weeks.

Partial response (PR): The product of the maximum perpendicular diameters of the tumor lesion is reduced by ≥50% and maintained for more than 4 weeks.

Improvement (MR): Tumor shrinkage ≥ 25% but less than 50%.

Stable (SD): Tumor shrinkage <25% or enlargement <25%.

Deterioration (PD): The product of the maximum perpendicular diameters of the tumor lesion is ≥ 25%, or new lesions appear.

Complete remission (CR): All lesions disappear completely and last for more than 4 weeks.

Partial response (PR): The product of the maximum perpendicular diameters of the tumor lesion is reduced by ≥50% and maintained for more than 4 weeks.

Stable (SD): The tumor has not shrunk or increased by more than 50%.

Progression (PD): Tumor lesions increase by more than 50%, or new lesions appear.